The Boston-based biotech is axing Phase II plans for its only clinical-stage asset, in a bid to maximise shareholder value.

Swiss-based Debiopharm has formed a research partnership with South Korea-based AI drug discovery company NetTargets.

As a part of its CPHI Frankfurt 2025 coverage, Pharmaceutical Technology ® interviewed Sriman Banerjee, PhD, executive ...

In the first part of this interview, Romanski tells PharmTech Group that while the field of oral dosage forms has not grown ...

"Massive sales for weight loss drugs spur Eli Lilly’s Q3" was originally created and published by Pharmaceutical Technology, ...

South Africa's biggest pharmaceutical producer Aspen Pharmacare said on Friday it had reached a 25 million euro ($29.2 ...

GSK’s fair value estimate has seen a modest increase, rising from $16.63 to $17.36 per share. The discount rate remains ...

Boston-based biotech firm Manifold Bio announced on Monday that it will partner with Swiss pharmaceutical giant Roche to develop a drug for neurological disease using technology driven by artificial ...

This move aims to establish an indigenous supply, moving away from current imports and scaling up production to a mandated ...

Researchers at the Indian Institute of Science (IISc) have developed a highly efficient cell-free enzyme system that converts ...

Siemens and Capgemini are expanding their partnership to create AI-based industrial technologies, said to boost efficiency, ...

Elevaris Medical Devices, a Contract Development and Manufacturing Organization for industry-leading multi-national healthcare companies, announced the appointment of its new Chief Engineering and ...